UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038815
Receipt number R000044207
Scientific Title Intratympanic steroid injection for sudden sesorineural hearing loss: a prospective observational study
Date of disclosure of the study information 2020/01/01
Last modified on 2020/11/11 17:10:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

middel ear injection of steroid for sudden deafness

Acronym

middle ear injection of steroid

Scientific Title

Intratympanic steroid injection for sudden sesorineural hearing loss: a prospective observational study

Scientific Title:Acronym

Intratympanic steroid injection for sudden sesorineural hearing loss

Region

Japan


Condition

Condition

sudden sensorineural hearing loss

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The standard 1st line therapy for sudden deafness is systemic administration of steroids. In many countries, patinets ineligible for systemic steroids and those who do not recover after systemic steroid therapy recieve intratympanic steroid injection.However, the intratympanic injection is not allowed in the healthcare systme of Japan. The objective of this study is to investigate prospectively the efficacy and adverse events of intratympanic steroid injection among Japanese patients with sudden deafness.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

improvement in pure tone audiometry at the end of the therapy, one month after the treatment, and 3months after the treatment

Key secondary outcomes

adverse events, such as tympanic membrane perforation


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

intratympanic injection of steroids
dexamethasone 5mg/ml
one administration per week.Total of 4 administrations

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1,age above 20
2,infomed consent by written documents
3,within 6 weeks from the onset
4, hearing loss of grade 3 or 4

ineligible for systemic steroids
or
unrecovered after systemic steroids

Key exclusion criteria

1, history of allergy to dexamethasone
2, history of allergy to EMLA cream
3, active infection in the middele ear

Target sample size

60


Research contact person

Name of lead principal investigator

1st name yukinori
Middle name
Last name takenaka

Organization

Kansai medical hospital

Division name

department of otolaryngology

Zip code

5600083

Address

1 Chome-1-7-2 Shinsenri Nishimachi, Toyonaka, Osaka

TEL

0668361199

Email

ysktakenaka@gmail.com


Public contact

Name of contact person

1st name yukinori
Middle name
Last name takenaka

Organization

Kansai medical hospital

Division name

department of otolaryngology

Zip code

5600083

Address

1 Chome-1-7-2 Shinsenri Nishimachi, Toyonaka, Osaka

TEL

0668361199

Homepage URL


Email

ysktakenaka@gmail.com


Sponsor or person

Institute

Kansai Medical Hospital

Institute

Department

Personal name



Funding Source

Organization

Kansai Medical Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

kansai medical hospital

Address

1 Chome-1-7-2 Shinsenri Nishimachi, Toyonaka, Osaka

Tel

0668361199

Email

takenaka@kansaimecidal-hp.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 12 Month 05 Day

Date of IRB

2019 Year 12 Month 05 Day

Anticipated trial start date

2020 Year 01 Month 04 Day

Last follow-up date

2022 Year 05 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 12 Month 06 Day

Last modified on

2020 Year 11 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044207


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name